Since Hsp90 modulates all six hallmarks of cancer simultaneously, it has become an attractive target for the development of cancer chemotherapeutics. In an effort to develop more efficacious compounds for Hsp90 inhibition, novobiocin analogues were prepared by replacing the central coumarin core with naphthalene, quinolinone, and quinoline surrogates. These modifications allowed for modification of the 2-position, which was previously unexplored. Biological evaluation of these compounds suggests a hydrophobic pocket about the 2-position of novobiocin. Anti-proliferative activities of these analogues against multiple cancer cell lines identified 2-alkoxyquinoline derivatives to exhibit improved activity
Inhibition of Hsp90 C-terminal function is an advantageous therapeutic paradigm for the treatment of...
As C−terminal inhibitors of a 90−kDa heat shock protein (Hsp90), novobiocin and its deri...
A series of triazole-containing novobiocin analogues has been designed, synthesized and their inhibi...
Since Hsp90 modulates all six hallmarks of cancer simultaneously, it has become an attractive target...
Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C...
Development of heat shock protein 90 (Hsp90) C‐terminal inhibitors has emerged as an exciting strate...
Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-...
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplish...
Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for...
The research described in this thesis focuses on heat shock protein 90 kDa (Hsp90), which is a molec...
Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatmen...
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ...
Dissertation (Ph.D.)--University of Kansas, Medicinal Chemistry, 2007.The 90 kDa heat shock proteins...
Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the trea...
The design, synthesis and biological evaluation of conformationally constrained coumermycin A1 analo...
Inhibition of Hsp90 C-terminal function is an advantageous therapeutic paradigm for the treatment of...
As C−terminal inhibitors of a 90−kDa heat shock protein (Hsp90), novobiocin and its deri...
A series of triazole-containing novobiocin analogues has been designed, synthesized and their inhibi...
Since Hsp90 modulates all six hallmarks of cancer simultaneously, it has become an attractive target...
Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C...
Development of heat shock protein 90 (Hsp90) C‐terminal inhibitors has emerged as an exciting strate...
Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-...
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplish...
Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for...
The research described in this thesis focuses on heat shock protein 90 kDa (Hsp90), which is a molec...
Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatmen...
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ...
Dissertation (Ph.D.)--University of Kansas, Medicinal Chemistry, 2007.The 90 kDa heat shock proteins...
Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the trea...
The design, synthesis and biological evaluation of conformationally constrained coumermycin A1 analo...
Inhibition of Hsp90 C-terminal function is an advantageous therapeutic paradigm for the treatment of...
As C−terminal inhibitors of a 90−kDa heat shock protein (Hsp90), novobiocin and its deri...
A series of triazole-containing novobiocin analogues has been designed, synthesized and their inhibi...